A Colorado family is calling for change and sharing their struggle after a clinical trial their son relied on suddenly ended.

Imagine a bruise that never heals — instead, it hardens into bone. A small swelling that doesn’t fade but permanently locks a ...

The agreement includes Ipsen’s investment in additional equipment at Quotient Sciences’ facility in Boothwyn, Pennsylvania, ...

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If ...

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approve ...

Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of garetosmab for adults with the ultra-rare genetic disorder fibrodysplasia ...

Garetosmab is a fully-human monoclonal antibody designed to bind and neutralize Activin A, a major promoter of heterotopic ossification in patients with FOP.

The companies have extended a commercial supply partnership for the manufacture of Sohonos (palovarotene), which is a ...

Quotient Sciences extends commercial manufacturing partnership with Ipsen for an ultra-rare disease treatment: Philadelphia, Pennsylvania Saturday, February 28, 2026, 10:00 Hrs [I ...

Expands Quotient's capabilities for handling and manufacturing highly potent API (HPAPI) drug molecules and products.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top gene therapy stocks to buy according to hedge funds.